What are clinical biomarkers?

Clinical biomarkers are biological molecules found in blood, other body fluids, or tissues that indicate a normal or abnormal process, or a condition or disease. They are used in clinical research and patient care to diagnose diseases, predict disease progression, and monitor treatment responses.

How big is the Clinical Biomarker Testing Market?

The global Clinical Biomarker Testing Market size was estimated at USD 873.6 Million in 2023 and is expected to reach USD 1750.9 Million in 2033.

What is the Clinical Biomarker Testing Market growth?

The global Clinical Biomarker Testing Market is expected to grow at a compound annual growth rate of 7.2%. From 2024 To 2033

Who are the key companies/players in the Clinical Biomarker Testing Market?

Some of the key players in the Clinical Biomarker Testing Markets are Abbott Laboratories, Bio Agilytix Labs, Eurofins Scientific, SGS SA, Charles River Laboratories, Labcorp Drug Development, Thermo Fisher Scientific Inc. (PPD, Inc.), ICON Plc, IQVIA, Syneos Health, Intertek Group Plc, Adaptive Biotechnologies, Becton Dickinson, Bio-Rad Laboratories, Agilent Technologies, Hologic, Merck and Co., Danaher Corporation, AbbVie Inc., and Other Key Players.

What is the importance of clinical biomarker testing?

Clinical biomarker testing is crucial for early disease detection, diagnosis, and personalized treatment plans. It helps in identifying specific biomarkers associated with diseases, enabling targeted therapies and improving patient outcomes.

Which industries primarily use clinical biomarker testing?

The pharmaceutical, biotechnology, and healthcare industries are the primary users of clinical biomarker testing. It is extensively used in drug development, clinical trials, and personalized medicine.

How does clinical biomarker testing impact patient care?

Clinical biomarker testing enables personalized treatment plans, improving the efficacy and safety of therapies. It aids in early disease detection, timely intervention, and continuous monitoring, leading to better patient outcomes and reduced healthcare costs.

Global Clinical Biomarker Testing Market By Services (Biomarker Assay Development & Validation, Flow Cytometry and Others) By Applications (Drug Discovery, Nutrigenomics, Toxicology Testing, Personalized Medicine and Functional Genomics) By Disease Types (Cancer, Metabolism, Infectious Disease, Cardiology, Neurology and Immunological Disease) By End-user (Pharmaceutical and Biotechnology Companies, Diagnostic Tool Companies, Healthcare IT/Big Data Companies, Clinical Laboratories, Academic and Research Institutes and CROS) and by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Published date: July 2024
Report ID: 84784
Number of Pages: 304
Format:

- Abbott Laboratories
- Bio Agilytix Labs
- Eurofins Scientific
- SGS SA
- Charles River Laboratories
- Labcorp Drug Development
- Thermo Fisher Scientific Inc. (PPD, Inc.)
- ICON Plc
- IQVIA
- Syneos Health
- Intertek Group Plc
- Adaptive Biotechnologies
- Becton Dickinson
- Bio-Rad Laboratories, Inc. Company Profile
- Agilent Technologies Inc. Company Profile
- Hologic
- Merck and Co.
- Danaher Corporation Company Profile
- AbbVie Inc. Company Profile
- Others.

Related Reports

Our Clients

Report ID 84784
Published Date July 2024
Rating
- ★★★★★
  
  ★★★★★
- (86)

Buy Now

Trusted by more than 17382 organizations globally

✖

Request a Sample Report

We'll get back to you as quickly as possible